Stock Scorecard
Stock Summary for Supernus Pharmaceuticals Inc (SUPN) - $51.77 as of 12/26/2025 3:49:13 PM EST
Total Score
6 out of 30
Safety Score
33 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for SUPN
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for SUPN
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for SUPN
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for SUPN
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for SUPN (33 out of 100)
| Stock Price Rating (Max of 10) | 9 |
| Historical Stock Price Rating (Max of 10) | 7 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 6 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 4 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 1 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for SUPN
Financial Details for SUPN
Company Overview |
|
|---|---|
| Ticker | SUPN |
| Company Name | Supernus Pharmaceuticals Inc |
| Country | N/A |
| Description | Supernus Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Rockville, Maryland, dedicated to developing and commercializing innovative therapies for central nervous system disorders, particularly epilepsy and migraine. The company's robust pipeline reflects a strong commitment to addressing significant unmet medical needs, positioning it favorably within a rapidly expanding market. With a focus on enhancing patient outcomes and quality of life, Supernus presents substantial growth potential for institutional investors seeking opportunities in the healthcare sector. |
| Sector Name | HEALTHCARE |
| Industry Name | DRUG MANUFACTURERS - SPECIALTY & GENERIC |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/3/2026 |
Stock Price History |
|
| Last Day Price | 51.77 |
| Price 4 Years Ago | 29.16 |
| Last Day Price Updated | 12/26/2025 3:49:13 PM EST |
| Last Day Volume | 209,018 |
| Average Daily Volume | 752,538 |
| 52-Week High | 57.65 |
| 52-Week Low | 29.16 |
| Last Price to 52 Week Low | 77.54% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 39.38 |
| Sector PE | 128.95 |
| 5-Year Average PE | 50.90 |
| Free Cash Flow Ratio | 19.61 |
| Industry Free Cash Flow Ratio | 14.27 |
| Sector Free Cash Flow Ratio | 31.21 |
| Current Ratio Most Recent Quarter | 1.80 |
| Total Cash Per Share | 2.64 |
| Book Value Per Share Most Recent Quarter | 18.38 |
| Price to Book Ratio | 2.83 |
| Industry Price to Book Ratio | 11.07 |
| Sector Price to Book Ratio | 43.34 |
| Price to Sales Ratio Twelve Trailing Months | 4.36 |
| Industry Price to Sales Ratio Twelve Trailing Months | 3.22 |
| Sector Price to Sales Ratio Twelve Trailing Months | 21.21 |
| Analyst Buy Ratings | 4 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 57,339,000 |
| Market Capitalization | 2,968,440,030 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 11.10% |
| Annual Earnings Growth | 5,512.84% |
| Reported EPS 12 Trailing Months | -0.34 |
| Reported EPS Past Year | 0.04 |
| Reported EPS Prior Year | 1.86 |
| Net Income Twelve Trailing Months | -19,117,000 |
| Net Income Past Year | 73,865,000 |
| Net Income Prior Year | 1,316,000 |
| Quarterly Revenue Growth YOY | 9.30% |
| 5-Year Revenue Growth | 11.00% |
| Operating Margin Twelve Trailing Months | 4.41% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 151,371,000 |
| Total Cash Past Year | 69,331,000 |
| Total Cash Prior Year | 75,054,000 |
| Net Cash Position Most Recent Quarter | -329,492,000 |
| Net Cash Position Past Year | -332,637,000 |
| Long Term Debt Past Year | 401,968,000 |
| Long Term Debt Prior Year | 401,968,000 |
| Total Debt Most Recent Quarter | 480,863,000 |
| Equity to Debt Ratio Past Year | 0.72 |
| Equity to Debt Ratio Most Recent Quarter | 0.69 |
| Total Stockholder Equity Past Year | 1,035,733,000 |
| Total Stockholder Equity Prior Year | 921,516,000 |
| Total Stockholder Equity Most Recent Quarter | 1,049,666,999 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 42,629,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 0.74 |
| Free Cash Flow Past Year | 171,226,000 |
| Free Cash Flow Prior Year | 110,534,000 |
Options |
|
| Put/Call Ratio | 7.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 0.72 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 33.73 |
System |
|
| Modified | 12/27/2025 8:44:27 AM EST |